PMID- 9352699
OWN - NLM
STAT- MEDLINE
DCOM- 19971216
LR  - 20220409
IS  - 0007-1331 (Print)
IS  - 0007-1331 (Linking)
VI  - 80
IP  - 4
DP  - 1997 Oct
TI  - Comparison of tamsulosin with alfuzosin in the treatment of patients with lower 
      urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic 
      benign prostatic hyperplasia). The European Tamsulosin Study Group.
PG  - 597-605
AB  - OBJECTIVE: To compare the efficacy and tolerability of the alpha 1 A-subtype 
      selective drug tamsulosin with the nonsubtype-selective agent alfuzosin in the 
      treatment of patients with lower urinary tract symptoms (LUTS) suggestive of 
      bladder outlet obstruction (BOO), often termed symptomatic benign prostatic 
      hyperplasia (BPH). PATIENTS AND METHODS: The study comprised 256 patients with 
      benign prostatic enlargement and LUTS suggestive of BOO (symptomatic BPH) who 
      received tamsulosin 0.4 mg once daily or alfuzosin 2.5 mg three times daily 
      during 12 weeks of treatment. The response was assessed by measurements of 
      maximum urinary flow rate (Qmax), a symptom score (Boyarsky) and blood pressure 
      at regular intervals. RESULTS: Tamsulosin and alfuzosin produced comparable 
      improvements in Qmax and total Boyarsky symptom score. Both treatments were well 
      tolerated with respect to adverse events. Tamsulosin had no statistically 
      significant effect on blood pressure compared with baseline but alfuzosin induced 
      a significant reduction in both standing and supine blood pressure, compared with 
      baseline (P < 0.05). CONCLUSION: Tamsulosin is the first adrenoceptor antagonist 
      that is selective for the alpha 1 A-subtype; this specificity may explain its 
      lack of effect on blood pressure compared with alfuzosin, an agent that is not 
      receptor subtype specific. Moreover, this finding may partly explain why 
      tamsulosin, in contrast to other currently available alpha 1-adrenoceptor 
      antagonists, can be administered without dose titration. Another advantage 
      compared with alfuzosin (and prazosin) is the once-daily dosing regimen of 
      tamsulosin.
FAU - Buzelin, J M
AU  - Buzelin JM
AD  - Hotel Dieu, Nantes, France.
FAU - Fonteyne, E
AU  - Fonteyne E
FAU - Kontturi, M
AU  - Kontturi M
FAU - Witjes, W P
AU  - Witjes WP
FAU - Khan, A
AU  - Khan A
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase III
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Br J Urol
JT  - British journal of urology
JID - 15740090R
RN  - 0 (Adrenergic alpha-Antagonists)
RN  - 0 (Quinazolines)
RN  - 0 (Sulfonamides)
RN  - 90347YTW5F (alfuzosin)
RN  - G3P28OML5I (Tamsulosin)
SB  - IM
EIN - Br J Urol 1998 Mar;81(3):510
MH  - Adrenergic alpha-Antagonists/adverse effects/*therapeutic use
MH  - Aged
MH  - Blood Pressure/drug effects
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prostatic Hyperplasia/*drug therapy/physiopathology
MH  - Quinazolines/adverse effects/*therapeutic use
MH  - Sulfonamides/adverse effects/*therapeutic use
MH  - Tamsulosin
MH  - Urination/physiology
EDAT- 1997/11/14 00:00
MHDA- 1997/11/14 00:01
CRDT- 1997/11/14 00:00
PHST- 1997/11/14 00:00 [pubmed]
PHST- 1997/11/14 00:01 [medline]
PHST- 1997/11/14 00:00 [entrez]
AID - 10.1046/j.1464-410x.1997.00205.x [doi]
PST - ppublish
SO  - Br J Urol. 1997 Oct;80(4):597-605. doi: 10.1046/j.1464-410x.1997.00205.x.